REPRO MED SYSTEMS INC: management transactions · United States · SEC (Form 4)

About REPRO MED SYSTEMS INC

REPRO MED SYSTEMS INC, now marketed under the KORU Medical Systems brand, is a U.S.-based medical technology company listed on the NASDAQ under ticker KRMD. Headquartered in Mahwah, New Jersey, United States, the company develops, manufactures, and commercializes large-volume subcutaneous infusion solutions primarily designed for home self-administration and ambulatory care settings. Its niche positioning gives it a focused role within specialty drug-delivery systems, with a model that also benefits from recurring revenue tied to consumables and accessories. Founded in 1980 as Repro Med Systems, the company has steadily evolved from its original identity into a more specialized infusion-technology business. It adopted the KORU Medical Systems brand in 2022, reflecting a strategic shift toward patient-centric, easy-to-use infusion solutions aligned with broader healthcare trends: the migration of therapies out of the hospital, cost containment, and improved patient convenience and quality of life. KORU’s core product platform is the Freedom Infusion System, which includes the Freedom60® and FreedomEdge® syringe infusion drivers, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets™. These products are used to administer selected immunoglobulin therapies and other compatible treatments, depending on approved labeling and setting. The company also operates a Pharma Services and Clinical Trials segment, supporting biopharmaceutical customers during feasibility work and clinical development, and offering customization capabilities for both clinical and commercial use. From a competitive standpoint, KORU is differentiated by its specialization in subcutaneous infusion, a category where patient usability, portability, and safety are critical. The company has built a presence in the United States and abroad, and international expansion remains a strategic priority. Its growth opportunities include broader product labeling, new therapy partnerships, and potential expansion into oncology-related use cases through regulatory submissions. This makes KRMD a specialized medical-device name rather than a broad diversified medtech platform. Recent developments have been constructive. In early 2026, management highlighted continued core-market share gains, strong international momentum, and expansion into prefilled syringe markets. KORU also announced a 510(k) submission intended to extend FreedomEDGE use to a commercialized oncology biologic, underscoring the company’s ambition to move beyond its legacy immunoglobulin base. For investors, KRMD offers exposure to long-term outpatient and home-infusion growth, but the investment case still depends on regulatory execution, commercial uptake, and successful expansion beyond its initial product and therapy concentration.